Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$3.10 USD
+0.11 (3.68%)
Updated Apr 26, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Ovid Therapeutics falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 106 | 129 | 188 | 72 | 77 |
Receivables | 0 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 2 | 3 | 3 | 2 |
Total Current Assets | 110 | 131 | 190 | 75 | 80 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 0 |
Investments & Advances | 18 | 6 | 2 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 1 | 1 |
Total Assets | 144 | 155 | 195 | 76 | 81 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 2 | 7 | 5 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 0 | 0 | 0 |
Accrued Expenses | 7 | 5 | 8 | 12 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 5 | 0 |
Total Current Liabilities | 11 | 7 | 15 | 22 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 10 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 15 | 16 | 0 | 0 | 0 |
Other Non-Current Liabilities | 30 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 56 | 23 | 15 | 32 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 366 | 358 | 351 | 338 | 283 |
Retained Earnings | -278 | -226 | -171 | -294 | -213 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 88 | 132 | 180 | 44 | 70 |
Total Liabilities & Shareholder's Equity | 144 | 155 | 195 | 76 | 81 |
Total Common Equity | 88 | 132 | 180 | 44 | 70 |
Shares Outstanding | 70.60 | 70.40 | 68.00 | 63.40 | 47.80 |
Book Value Per Share | 1.24 | 1.88 | 2.64 | 0.69 | 1.46 |
Fiscal Year End for Ovid Therapeutics falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 106 | 87 | 97 | 118 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 5 | 6 | 2 |
Total Current Assets | NA | 110 | 92 | 102 | 120 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 18 | 16 | 16 | 6 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 2 | 2 | 2 |
Total Assets | NA | 144 | 125 | 136 | 143 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 1 | 4 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 1 | 1 | 1 | 1 |
Accrued Expenses | NA | 7 | 6 | 5 | 4 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 11 | 9 | 10 | 7 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 15 | 15 | 15 | 16 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 56 | 24 | 26 | 22 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 366 | 364 | 362 | 360 |
Retained Earnings | NA | -278 | -263 | -251 | -239 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 88 | 101 | 111 | 121 |
Total Liabilities & Shareholder's Equity | NA | 144 | 125 | 136 | 143 |
Total Common Equity | 0 | 88 | 101 | 111 | 121 |
Shares Outstanding | 70.70 | 70.60 | 70.60 | 70.50 | 70.50 |
Book Value Per Share | 0.00 | 1.24 | 1.43 | 1.57 | 1.72 |